Skip to main content

Table 3 Methylation of DNA from liquid biopsy as biomarkers for lung cancer prognosis and prediction

From: Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer

DNA methylation Body fluid Method Number of cases Number of controls Main findings References
SHOX2 plasma qMSP 36 - negative impact on survival [87]
RARB2/RASSF1A plasma qMSP 26 - Reduced after neoadjuvant chemotherapy and surgery; [78]
RARB2 plasma qMSP 26 - increased before recurrence [78]
RASSF1A/APC plasma qMSP 316 - Elevated after chemotherapy; correlated with good response to cisplatin [89]
DCLK1 plasma qMSP 65 95 negative impact on survival [17]
BRMS1 plasma qMSP 122 24 negative impact on survival [86]
SOX17 plasma qMSP 122 24 negative impact on survival [45]
SFN serum qMSP 115 - positive impact on survival with platinum-based chemotherapy [88]
CHFR serum qMSP 366 - negative impact on survival with second-line EGFR-TKIs, compared to chemotherapy [90]
smoCpGs Whole blood HM450K 60 1505 predict LC mortality (HR7.82) [110]
APC/RASSF1A/CDH13/CDKN2A Plasma MSP 45 - negative impact on PFS and OS [31]
  1. qMSP quantitative methylation-specific PCR, HM450K HumanMethylation450K BeadChip Assay, LC lung cancer, PFS progression free survival, OS overall survival, SHOX2 short stature homebox 2, RARβ2 retinoic acid receptor B2, RASSF1A ras association domain family 1 isoform A, APC adenomatous polyposis coli, DCLK1 doublecortin like kinase 1, BRMS1 breast cancer metastasis suppressor-1, SOX17 (sex determining region Y)-box 17, SFN stratifin, CHFR checkpoint with forkhead and ring finger domains, smoCpGs smoking-associated CpGs, caCpGs Lung cancer-related CpGs, CDH13 cadherin 13, CDKN2A cyclin dependent kinase inhibitor 2A